

BIOGEN IDEC INC.  
Form 10-Q  
October 21, 2009

Table of Contents

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**Form 10-Q**

(Mark One)

- ☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**  
**For the quarterly period ended September 30, 2009**
- OR**
- ☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**Commission File Number 0-19311**

**BIOGEN IDEC INC.**

*(Exact name of registrant as specified in its charter)*

**Delaware**

*(State or other jurisdiction of  
incorporation or organization)*

**33-0112644**

*(I.R.S. Employer  
Identification No.)*

**14 Cambridge Center, Cambridge, MA 02142**  
**(617) 679-2000**

*(Address, including zip code, and telephone number, including  
area code, of registrant's principal executive offices)*

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files): Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Edgar Filing: BIOGEN IDEC INC. - Form 10-Q

Large accelerated filer ☒

Accelerated filer ☐

Non-accelerated filer ☐

Smaller reporting company ☐

(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes ☐ No ☒

The number of shares of the issuer's Common Stock, \$0.0005 par value, outstanding as of October 14, 2009, was 289,198,517 shares.

---

**BIOGEN IDEC INC.**

**FORM 10-Q Quarterly Report  
For the Quarterly Period Ended September 30, 2009**

**TABLE OF CONTENTS**

	<b>Page</b>
<b><u>PART I FINANCIAL INFORMATION</u></b>	
Item 1. Financial Statements (unaudited)	
Consolidated Statements of Income For the Three and Nine Months Ended September 30, 2009 and 2008	3
Consolidated Balance Sheets As of September 30, 2009 and December 31, 2008	4
Consolidated Statements of Cash Flows For the Nine Months Ended September 30, 2009 and 2008	5
Notes to Consolidated Financial Statements	6
<u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	45
<u>Item 3. Quantitative and Qualitative Disclosures About Market Risk</u>	64
<u>Item 4. Controls and Procedures</u>	64
<b><u>PART II OTHER INFORMATION</u></b>	
<u>Item 1. Legal Proceedings</u>	64
<u>Item 1A. Risk Factors</u>	64
<u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</u>	75
<u>Item 6. Exhibits</u>	75
<u>Signatures</u>	76
<u>EX-31.1 SECTION 302 CERTIFICATION OF CEO</u>	
<u>EX-31.2 SECTION 302 CERTIFICATION OF CFO</u>	
<u>EX-32.1 SECTION 906 CERTIFICATION OF CEO &amp; CFO</u>	
<u>EX-101 INSTANCE DOCUMENT</u>	
<u>EX-101 SCHEMA DOCUMENT</u>	
<u>EX-101 CALCULATION LINKBASE DOCUMENT</u>	
<u>EX-101 LABELS LINKBASE DOCUMENT</u>	
<u>EX-101 PRESENTATION LINKBASE DOCUMENT</u>	
<u>EX-101 DEFINITION LINKBASE DOCUMENT</u>	

**Table of Contents****PART I FINANCIAL INFORMATION**

**BIOGEN IDEC INC. AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF INCOME**  
*(unaudited, in thousands, except per share amounts)*

	<b>For the Three Months Ended September 30, 2009</b>		<b>For the Nine Months Ended September 30, 2009</b>		<b>2008</b>	
Revenues:						
Product	\$	801,689	\$	758,260	\$	2,326,067
Unconsolidated joint business		283,919		298,979		838,307
Other revenues		34,910		35,725		85,918
Total revenues		1,120,518		1,092,964		3,250,292
Costs and expenses:						
Cost of sales, excluding amortization of acquired intangible assets		93,486		107,493		282,404
Research and development		304,055		268,800		999,986
Selling, general and administrative		226,755		232,824		669,415
Collaboration profit sharing		60,697		43,533		152,608
Amortization of acquired intangible assets		51,347		94,464		233,830
Acquired in-process research and development						25,000
Total costs and expenses		736,340		747,114		2,338,243
Income from operations		384,178		345,850		912,049
Other income (expense), net		9,360		(23,713)		30,886
Income before income tax expense		393,538		322,137		942,935
Income tax expense		113,936		114,337		271,869
Net income		279,602		207,800		671,066
Net income attributable to noncontrolling interest, net of tax		1,939		1,012		6,571
Net income attributable to Biogen Idec Inc.	\$	277,663	\$	206,788	\$	664,495
Basic earnings per share attributable to Biogen Idec Inc.	\$	0.96	\$	0.71	\$	2.30
Diluted earnings per share attributable to Biogen Idec Inc.	\$	0.95	\$	0.70	\$	2.28
					\$	1.97
						1.95

Weighted-average shares used in calculating:

Basic earnings per share attributable to

Biogen Idec Inc.	288,917	291,408	288,416	292,613
------------------	---------	---------	---------	---------

Diluted earnings per share attributable to

Biogen Idec Inc.	291,037	293,921	290,368	295,515
------------------	---------	---------	---------	---------

See accompanying notes to these unaudited consolidated financial statements.

**Table of Contents**

**BIOGEN IDEC INC. AND SUBSIDIARIES**  
**CONSOLIDATED BALANCE SHEETS**  
*(unaudited, in thousands, except per share amounts)*

	As of September 30, 2009	As of December 31, 2008
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents	\$ 585,788	\$ 622,385
Marketable securities	821,888	719,586
Collateral received for loaned securities		29,991
Accounts receivable, net	550,995	446,665
Due from unconsolidated joint business	193,279	206,925
Loaned securities		29,446
Inventory	278,686	263,602
Other current assets	141,623	139,400
Total current assets	2,572,259	2,458,000
Marketable securities	1,497,447	891,406
Property, plant and equipment, net	1,634,696	1,594,754
Intangible assets, net	1,927,115	2,161,058
Goodwill	1,138,621	1,138,621
Investments and other assets	256,299	235,152
Total assets	\$ 9,026,437	\$ 8,478,991
<b>LIABILITIES AND EQUITY</b>		
Current liabilities:		
Collateral payable on loaned securities	\$	\$ 29,991
Accounts payable	108,547	107,417
Taxes payable	59,961	223,260
Accrued expenses and other	537,408	534,887
Current portion of notes payable and line of credit	15,452	27,667
Total current liabilities	721,368	923,222
Notes payable and line of credit	1,085,844	1,085,431
Long-term deferred tax liability	289,654	356,017
Other long-term liabilities	331,761	280,369
Total liabilities	2,428,627	2,645,039
Commitments and contingencies (Notes 12, 14 and 15)		
Equity:		

Edgar Filing: BIOGEN IDEC INC. - Form 10-Q

Preferred stock, par value \$0.001 per share		
Common stock, par value \$0.0005 per share	149	149
Additional paid-in capital	6,184,315	6,073,957
Accumulated other comprehensive income (loss)	37,114	(11,106)
Retained earnings	781,321	270,180
Treasury stock, at cost	(438,710)	(527,097)
Total Biogen Idec Inc. shareholders' equity	6,564,189	5,806,083
Noncontrolling interest	33,621	27,869
Total equity	6,597,810	5,833,952
Total liabilities and equity	\$ 9,026,437	\$ 8,478,991

See accompanying notes to these unaudited consolidated financial statements.



Table of Contents

**BIOGEN IDEC INC. AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**  
*(unaudited, in thousands)*

	<b>For the Nine Months Ended September 30,</b>	
	<b>2009</b>	<b>2008</b>
Cash flows from operating activities:		
Net income	\$ 671,066	\$ 581,680
Adjustments to reconcile net income to net cash flows from operating activities:		
Depreciation and amortization of property, plant and equipment and intangible assets	334,761	340,042
Acquired in-process research and development		25,000
Share-based compensation	119,902	104,339
Non-cash interest (income) expense and foreign exchange remeasurement loss (gain), net	(12,861)	(11,288)
Deferred income taxes	(72,580)	(57,591)
Realized loss (gain) on sale of marketable securities and strategic investments	(17,185)	3,774
Write-down of inventory to net realizable value	13,431	22,472
Impairment of marketable securities, investments and other assets	9,866	31,502
Excess tax benefit from stock options	(3,194)	(27,424)
Changes in operating assets and liabilities, net:		
Accounts receivable	(96,215)	(95,337)
Due from unconsolidated joint business	13,646	(29,856)
Inventory	(25,195)	(34,376)
Other assets	8,555	24,898
Accrued expenses and other current liabilities	(40,565)	155,437
Other liabilities and taxes payable	(110,706)	121,928
Net cash flows provided by operating activities	792,726	1,155,200
Cash flows from investing activities:		
Purchases of marketable securities	(3,001,156)	(1,801,056)
Proceeds from sales and maturities of marketable securities	2,334,093	2,135,065
Collateral received under securities leading	29,991	30,080
Acquisitions, net of cash acquired		(25,000)
Purchases of property, plant and equipment	(110,129)	(221,961)
Proceeds from the sale of property, plant and equipment		16
Purchases of other investments	(36,519)	(17,260)
Proceeds from the sale of a strategic equity investment	6,067	
Net cash flows (used in) provided by investing activities	(777,653)	99,884
Cash flows from financing activities:		
Purchase of treasury stock	(57,631)	(559,767)
Proceeds from issuance of stock for share-based compensation arrangements	33,236	167,032
Change in cash overdraft	7,497	18,052

Edgar Filing: BIOGEN IDEC INC. - Form 10-Q

Excess tax benefit from stock options	3,194	27,424
Proceeds from borrowings		986,980
Repayment of borrowings	(10,867)	(1,512,474)
Obligation under securities lending	(29,991)	(30,080)
Net cash flows used in financing activities	(54,562)	(902,833)
Net (decrease) increase in cash and cash equivalents	(39,489)	352,251
Effect of exchange rate changes on cash and cash equivalents	2,892	(1,212)
Cash and cash equivalents, beginning of the period	622,385	659,662
Cash and cash equivalents, end of the period	\$ 585,788	\$ 1,010,701

See accompanying notes to these unaudited consolidated financial statements.

**Table of Contents**

**BIOGEN IDEC INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**(*unaudited*)**

**1. Business Overview**

***Overview***

Biogen Idec Inc. ( Biogen Idec, we, us or the Company ) is a global biotechnology company that creates new standards of care in therapeutic areas with high unmet medical needs. We currently have four marketed products: AVONEX®, RITUXAN®, TYSABRI®, and FUMADERM™. Our marketed products are used for the treatment of multiple sclerosis, or MS, non-Hodgkin's lymphoma, or NHL, rheumatoid arthritis, or RA, Crohn's disease and psoriasis.

***Basis of Presentation***

In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments, consisting of only normal recurring accruals, necessary for a fair statement of our financial position, results of operations and cash flows. The information included in this quarterly report on Form 10-Q should be read in conjunction with our consolidated financial statements and the accompanying notes included in our annual report on Form 10-K for the year ended December 31, 2008. Our accounting policies are described in Notes to Consolidated Financial Statements in our 2008 annual report on Form 10-K and updated, as necessary, in this Form 10-Q. The year-end consolidated balance sheet data presented for comparative purposes was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States. The results of operations for the three and nine months ended September 30, 2009 are not necessarily indicative of the operating results for the full year or for any other subsequent interim period.

In June 2009, the Financial Accounting Standards Board, or FASB, issued the FASB Accounting Standards Codification, or Codification. Effective this quarter, the Codification became the single source for all authoritative generally accepted accounting principles, or GAAP, recognized by the FASB and is required to be applied to financial statements issued for interim and annual periods ending after September 15, 2009. The Codification does not change GAAP and did not impact our financial position or results of operations.

Effective January 1, 2009, we adopted a newly issued accounting standard for noncontrolling interests. In accordance with the accounting standard, we changed the accounting and reporting for our minority interests (now called noncontrolling interest) in our consolidated financial statements. Upon adoption, certain prior period amounts have been reclassified to conform to the current period financial statement presentation. These reclassifications did not have a material impact on our previously reported financial position or results of operations. Refer to Note 9, *Equity*, and Note 13, *Other Income (Expense), Net*, of this Form 10-Q for additional information on the adoption of this standard.

***Principles of Consolidation***

The consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and of our joint ventures in Italy and Switzerland, Biogen Dompé SRL and Biogen Dompé Switzerland GmbH, respectively. We consolidate variable interest entities in which we are the primary beneficiary. For such consolidated entities in which we own less than a 100% interest, we record net income attributable to noncontrolling interest (minority interest) in our consolidated statements of income equal to the percentage of ownership of the respective noncontrolling owners. All material intercompany balances and transactions have been eliminated in consolidation.

*Use of Estimates*

The preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States requires our management to make estimates and judgments that may affect the

**Table of Contents**

**BIOGEN IDEC INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
*(unaudited, continued)*

reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates and judgments, including those related to revenue recognition and related allowances, marketable securities, derivatives and hedging activities, inventory, impairments of long-lived assets including intangible assets, impairments of goodwill, income taxes including the valuation allowance for deferred tax assets, valuation of investments, research and development expenses, contingencies and litigation, and share-based payments. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions.

***Subsequent Events***

Allowance for loan losses

806

849

967

Allowance for credit losses on lending-related commitments (a)

30

32

44

Total allowance for credit losses

	836
	881
	1,011
Allowance for loan losses/Total loans	
	2.06
%	
	2.17
%	
	2.38
%	
Allowance for loan losses/Nonperforming loans	
	83
	82
Table of Contents	14

---

(a) *Included in Accrued expenses and other liabilities on the consolidated balance sheets.*

- more -

---

**COMERICA REPORTS SECOND QUARTER 2011 NET INCOME OF \$96 MILLION 5**

**Balance Sheet and Capital Management**

Total assets and common shareholders' equity were \$54.1 billion and \$6.0 billion, respectively, at June 30, 2011, compared to \$55.0 billion and \$5.9 billion, respectively, at March 31, 2011. There were approximately 177 million common shares outstanding at June 30, 2011. Comerica did not repurchase any shares of common stock in the open market in the second quarter 2011 under the share repurchase program due to the pending Sterling acquisition. Management expects to resume repurchases in the third quarter 2011.

Comerica's tangible common equity ratio was 10.90 percent at June 30, 2011, an increase of 47 basis points from March 31, 2011. The estimated Tier 1 capital ratio increased 18 basis points, to 10.53 percent at June 30, 2011, from March 31, 2011.

**Second-Half 2011 Outlook (Combined Comerica and Sterling Results) Compared to First-Half 2011 (Comerica Only Results)**

For the second half of 2011, management expects the following combined results, based on the incorporation of the projected results of Sterling operations from the expected acquisition closing date of July 28, 2011 through year-end 2011, compared to Comerica-only results for the first half of 2011, assuming a continuation of modest growth in the economy. The acquisition is subject to customary closing conditions. The estimated purchase accounting impacts incorporated in this outlook are preliminary and may not be indicative of actual amounts that will be recorded as additional information becomes available and as additional analyses are performed.

- A mid-single digit increase in average loans due to the acquisition of Sterling loans at fair value.
- Average earning assets of approximately \$52.5 billion, reflecting increases, primarily related to Sterling, in average loans and average investment securities available-for-sale, partially offset by a decrease in excess liquidity.
- An average net interest margin of 3.35 percent to 3.40 percent, reflecting the benefit from the accretion of the purchase discount on the acquired Sterling loan portfolio (\$35 million to \$45 million; 13 basis points to 17 basis points), a reduction in excess liquidity, no increase in the Federal Funds rate, and LIBOR consistent with second quarter 2011 levels.
- Net credit-related charge-offs between \$165 million and \$185 million for the second half of 2011. The provision for credit losses is expected to be between \$65 million and \$85 million for the second half of 2011.
- A mid-single digit decline in noninterest income in the second half of 2011 compared to the first half of 2011, primarily due to the impact of regulatory changes, partially offset by the inclusion of Sterling.
- Excluding merger and restructuring charges, a high single-digit increase in noninterest expenses in the second half of 2011 compared to the first half of 2011, primarily due to the addition of Sterling.
- Total merger and restructuring charges of approximately \$80 million, after-tax, with about \$25 million, after-tax, recognized in each of the third and fourth quarters of 2011, and the remainder recognized in 2012.
- Total acquisition synergies of approximately 35 percent of Sterling expenses, or about \$56 million, with the majority realized in 2012.



## Edgar Filing: BIOGEN IDEC INC. - Form 10-Q

- For the second half of 2011, income tax expense to approximate 36 percent of income before income taxes less approximately \$33 million in tax benefits.
- Continue share repurchase program that, combined with dividend payments, results in a payout up to 50 percent of full-year earnings.

-more-

---

**COMERICA REPORTS SECOND QUARTER 2011 NET INCOME OF \$96 MILLION 6****Business Segments**

Comerica's operations are strategically aligned into three major business segments: the Business Bank, the Retail Bank, and Wealth Management. The Finance Division is also included as a segment. The financial results below are based on the internal business unit structure of the Corporation and methodologies in effect at June 30, 2011 and are presented on a fully taxable equivalent (FTE) basis. The accompanying narrative addresses second quarter 2011 results compared to first quarter 2011.

The following table presents net income (loss) by business segment.

(dollar amounts in millions)		2nd Qtr 11		1st Qtr 11		2nd Qtr 10			
Business Bank	\$	176	95%	\$	167	93%	\$	135	98%
Retail Bank		(3)	(2)		(2)	(1)		(3)	(2)
Wealth Management		12	7		14	8		5	4
		185	100%		179	100%		137	100%
Finance		(87)			(76)			(57)	
Other (a)		(2)						(10)	
Total	\$	96		\$	103		\$	70	

(a) Includes discontinued operations and items not directly associated with the three major business segments or the Finance Division.

***Business Bank***

(dollar amounts in millions)	2nd Qtr '11		1st Qtr '11		2nd Qtr '10	
Net interest income (FTE)	\$	342	\$	341	\$	351
Provision for loan losses		6		18		83
Noninterest income		79		77		78
Noninterest expenses		158		160		157
Net income		176		167		135
Net credit-related charge-offs		54		73		113
Selected average balances:						
Assets		29,893		30,091		30,609
Loans		29,380		29,609		30,353
Deposits		20,396		20,084		19,069
Net interest margin		4.65%		4.66%		4.63%

- Average loans decreased \$229 million, reflecting increases in Middle Market, Global Corporate Banking and Specialty Businesses, more than offset by decreases in Commercial Real Estate and National Dealer Services.

## Edgar Filing: BIOGEN IDEC INC. - Form 10-Q

- Average deposits increased \$312 million, primarily due to increases in Specialty Businesses and Global Corporate Banking, partially offset by a decrease in Middle Market.
- The net interest margin of 4.65 percent decreased one basis point, primarily due to a decrease in deposit spreads.
- The provision for loan losses decreased \$12 million, primarily reflecting decreases in Middle Market and Commercial Real Estate, partially offset by increases in Global Corporate Banking and Specialty Businesses.

-more-

---

**COMERICA REPORTS SECOND QUARTER 2011 NET INCOME OF \$96 MILLION 7*****Retail Bank***

(dollar amounts in millions)	2nd Qtr 11	1st Qtr 11	2nd Qtr 10
Net interest income (FTE)	\$ 141	\$ 139	\$ 134
Provision for loan losses	24	23	20
Noninterest income	46	42	42
Noninterest expenses	162	162	160
Net loss	(3)	(2)	(3)
Net credit-related charge-offs	22	23	22
Selected average balances:			
Assets	5,453	5,558	5,937
Loans	4,999	5,106	5,446
Deposits	17,737	17,360	16,930
Net interest margin	3.22%	3.25%	3.17%

- Average loans decreased \$107 million, reflecting declines across all markets and business lines.
- Average deposits increased \$377 million, primarily due to increases in transaction and money market deposits, partially offset by a decrease in customer certificates of deposit.
- The net interest margin of 3.22 percent decreased three basis points, primarily due to a decrease in deposit spreads.
- Noninterest income increased \$4 million, reflecting nominal increases in numerous categories.

***Wealth Management***

(dollar amounts in millions)	2nd Qtr 11	1st Qtr 11	2nd Qtr 10
Net interest income (FTE)	\$ 48	\$ 44	\$ 45
Provision for loan losses	14	8	19
Noninterest income	63	64	61
Noninterest expenses	76	78	79
Net income	12	14	5
Net credit-related charge-offs	14	5	11
Selected average balances:			
Assets	4,728	4,809	4,903
Loans	4,742	4,807	4,840
Deposits	2,978	2,800	2,924
Net interest margin	4.07%	3.76%	3.73%

## Edgar Filing: BIOGEN IDEC INC. - Form 10-Q

- Average loans decreased \$65 million.
- Average deposits increased \$178 million, primarily reflecting increases in noninterest-bearing transaction accounts.
- The net interest margin of 4.07 percent increased 31 basis points, primarily due to increases in loan spreads and deposit balances.
- The provision for loan losses increased \$6 million, due to an increase in Private Banking in the Western Market.

- more -

---

**COMERICA REPORTS SECOND QUARTER 2011 NET INCOME OF \$96 MILLION 8****Geographic Market Segments**

Comerica also provides market segment results for four primary geographic markets: Midwest, Western, Texas and Florida. In addition to the four primary geographic markets, Other Markets and International are also reported as market segments. The financial results below are based on methodologies in effect at June 30, 2011 and are presented on a fully taxable equivalent (FTE) basis. The accompanying narrative addresses second quarter 2011 results compared to first quarter 2011.

The following table presents net income (loss) by market segment.

(dollar amounts in millions)	2nd Qtr 11		1st Qtr 11		2nd Qtr 10				
Midwest	\$	62	34%	\$	53	30%	\$	61	44%
Western		50	27		51	28		38	28
Texas		33	18		29	16		26	19
Florida		(5)	(3)		(4)	(2)		(8)	(6)
Other Markets		30	16		38	21		4	3
International		15	8		12	7		16	12
		185	100%		179	100%		137	100%
Finance & Other Businesses (a)		(89)			(76)			(67)	
Total	\$	96		\$	103		\$	70	

(a) Includes discontinued operations and items not directly associated with the geographic markets.

***Midwest Market***

(dollar amounts in millions)	2nd Qtr 11		1st Qtr 11		2nd Qtr 10	
Net interest income (FTE)	\$	204	\$	203	\$	211
Provision for loan losses		15		34		34
Noninterest income		100		100		97
Noninterest expenses		183		188		180
Net income		62		53		61
Net credit-related charge-offs		37		46		44
Selected average balances:						
Assets		14,267		14,307		14,626
Loans		14,051		14,104		14,592
Deposits		18,319		18,230		17,988
Net interest margin		4.46%		4.49%		4.66%

## Edgar Filing: BIOGEN IDEC INC. - Form 10-Q

- Average loans decreased \$53 million, with increases in Middle Market and Global Corporate Banking more than offset by declines in most other business lines.
- Average deposits increased \$89 million, primarily due to increases in Personal Banking, Small Business Banking, Commercial Real Estate and Middle Market, partially offset by decreases in Global Corporate Banking and Specialty Businesses.
- The net interest margin of 4.46 percent decreased three basis points, primarily due to decreases in deposit spreads and loan balances, partially offset by an increase in loan spreads.
- The provision for loan losses decreased \$19 million, primarily reflecting decreases in Middle Market and Commercial Real Estate, partially offset by an increase in Global Corporate Banking.
- Noninterest expenses decreased \$5 million, primarily due to decreases in other real estate expenses, net allocated corporate overhead expenses and FDIC insurance expense, partially offset by an increase in the provision for credit losses on lending-related commitments.

- more -

---

**COMERICA REPORTS SECOND QUARTER 2011 NET INCOME OF \$96 MILLION 9**
**Western Market**

(dollar amounts in millions)	2nd Qtr 11	1st Qtr 11	2nd Qtr 10
Net interest income (FTE)	\$ 166	\$ 164	\$ 163
Provision for loan losses	20	11	27
Noninterest income	37	37	33
Noninterest expenses	108	109	110
Net income	50	51	38
Net credit-related charge-offs	26	26	47
Selected average balances:			
Assets	12,329	12,590	13,006
Loans	12,121	12,383	12,792
Deposits	12,458	12,235	11,951
Net interest margin	5.35%	5.37%	5.13%

- Average loans decreased \$262 million, primarily due to decreases in National Dealer Services, Commercial Real Estate and Private Banking, partially offset by increases in Middle Market and Global Corporate Banking.
- Average deposits increased \$223 million, primarily due to increases in Specialty Businesses and Private Banking, partially offset by a decrease in Middle Market.
- The net interest margin of 5.35 percent decreased two basis points, primarily due to a decrease in loan balances.
- The provision for loan losses increased \$9 million, primarily due to increases in Private Banking and Specialty Businesses.

**Texas Market**

(dollar amounts in millions)	2nd Qtr 11	1st Qtr 11	2nd Qtr 10
Net interest income (FTE)	\$ 89	\$ 87	\$ 81
Provision for loan losses	(2)	4	(1)
Noninterest income	25	23	23
Noninterest expenses	63	61	65
Net income	33	29	26
Total net credit-related charge-offs	3	8	8
Selected average balances:			
Assets	7,081	7,031	6,652
Loans	6,871	6,824	6,428
Deposits	6,175	5,786	5,316



## Edgar Filing: BIOGEN IDEC INC. - Form 10-Q

Net interest margin	5.19%	5.17%	5.05%
---------------------	-------	-------	-------

- Average loans increased \$47 million, primarily due to increases in Middle Market and Global Corporate Banking, partially offset by a decrease in Commercial Real Estate.
- Average deposits increased \$389 million, reflecting increases across most business lines.
- The net interest margin of 5.19 percent increased two basis points, primarily due to increases in loan spreads and deposit balances, partially offset by a decrease in deposit spreads.
- The provision for loan losses decreased \$6 million, with decreases across most business lines.

- more -

---

**COMERICA REPORTS SECOND QUARTER 2011 NET INCOME OF \$96 MILLION 10*****Florida Market***

<b>(dollar amounts in millions)</b>	<b>2nd Qtr 11</b>	<b>1st Qtr 11</b>	<b>2nd Qtr 10</b>
Net interest income (FTE)	\$ 12	\$ 11	\$ 12
Provision for loan losses	11	8	17
Noninterest income	4	4	4
Noninterest expenses	12	12	12
Net loss	(5)	(4)	(8)
Net credit-related charge-offs	15	8	7
<b>Selected average balances:</b>			
Assets	1,534	1,553	1,576
Loans	1,565	1,580	1,575
Deposits	396	367	404
Net interest margin	3.14%	2.82%	2.94%

- Average loans decreased \$15 million, primarily due to decreases in Commercial Real Estate and National Dealer Services, partially offset by increases in Global Corporate Banking and Private Banking.
- Average deposits increased \$29 million, primarily due to an increase in Private Banking.
- The net interest margin of 3.14 percent increased 32 basis points, primarily due to increases in loan spreads and deposit balances.
- The provision for loan losses increased \$3 million, primarily due to increases in Middle Market, Commercial Real Estate and Private Banking.

**Conference Call and Webcast**

Comerica will host a conference call to review second quarter 2011 financial results at 7 a.m. CT Tuesday, July 19, 2011. Interested parties may access the conference call by calling (800) 309-2262 or (706) 679-5261 (event ID No. 77355589). The call and supplemental financial information can also be accessed on the Internet at [www.comerica.com](http://www.comerica.com). A telephone replay will be available approximately two hours following the conference call through July 31, 2011. The conference call replay can be accessed by calling (800) 642-1687 or (706) 645-9291 (event ID No. 77355589). A replay of the Webcast can also be accessed via Comerica's Investor Relations page at [www.comerica.com](http://www.comerica.com).

Comerica Incorporated is a financial services company headquartered in Dallas, Texas, and strategically aligned by three major business segments: the Business Bank, the Retail Bank, and Wealth Management. Comerica focuses on relationships and helping people and businesses be successful. In addition to Texas, Comerica Bank locations can be found in Arizona, California, Florida and Michigan, with select businesses operating in several other states, as well as in Canada and Mexico.

## Edgar Filing: BIOGEN IDEC INC. - Form 10-Q

This press release contains both financial measures based on accounting principles generally accepted in the United States (GAAP) and non-GAAP based financial measures, which are used where management believes it to be helpful in understanding Comerica's results of operations or financial position. Where non-GAAP financial measures are used, the comparable GAAP financial measure, as well as the reconciliation to the comparable GAAP financial measure, can be found in this press release. These disclosures should not be viewed as a substitute for operating results determined in accordance with GAAP, nor are they necessarily comparable to non-GAAP performance measures that may be presented by other companies.

- more -

---

**COMERICA REPORTS SECOND QUARTER 2011 NET INCOME OF \$96 MILLION 11****Forward-looking Statements**

Any statements in this news release that are not historical facts are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Words such as anticipates, believes, feels, expects, estimates, seeks, strives, plans, intends, outlook, for, target, mission, assume, achievable, potential, strategy, goal, aspiration, opportunity, initiative, outcome, continue, re, objective, pending, looks forward and variations of such words and similar expressions, or future or conditional verbs such as will, would, should, could, might, can, may or similar expressions, as they relate to Comerica or its management, are intended to identify forward-looking statements. These forward-looking statements are predicated on the beliefs and assumptions of Comerica's management based on information known to Comerica's management as of the date of this news release and do not purport to speak as of any other date. Forward-looking statements may include descriptions of plans and objectives of Comerica's management for future or past operations, products or services, and forecasts of Comerica's revenue, earnings or other measures of economic performance, including statements of profitability, business segments and subsidiaries, estimates of credit trends and global stability. Such statements reflect the view of Comerica's management as of this date with respect to future events and are subject to risks and uncertainties. Should one or more of these risks materialize or should underlying beliefs or assumptions prove incorrect, Comerica's actual results could differ materially from those discussed. Factors that could cause or contribute to such differences are changes in general economic, political or industry conditions and related credit and market conditions; changes in trade, monetary and fiscal policies, including the interest rate policies of the Federal Reserve Board; adverse conditions in the capital markets; the interdependence of financial service companies; changes in regulation or oversight, including the effects of recently enacted legislation, actions taken by or proposed by the U.S. Treasury, the Board of Governors of the Federal Reserve System, the Texas Department of Banking and the Federal Deposit Insurance Corporation, legislation or regulations enacted in the future, and the impact and expiration of such legislation and regulatory actions; unfavorable developments concerning credit quality; the proposed acquisition of Sterling Bancshares, Inc. (Sterling), or any future acquisitions; the effects of more stringent capital or liquidity requirements; declines or other changes in the businesses or industries in which Comerica has a concentration of loans, including, but not limited to, the automotive production industry and the real estate business lines; the implementation of Comerica's strategies and business models, including the anticipated performance of any new banking centers; Comerica's ability to utilize technology to efficiently and effectively develop, market and deliver new products and services; operational difficulties or information security problems; changes in the financial markets, including fluctuations in interest rates and their impact on deposit pricing; the entry of new competitors in Comerica's markets; changes in customer borrowing, repayment, investment and deposit practices; management's ability to maintain and expand customer relationships; management's ability to retain key officers and employees; the impact of legal and regulatory proceedings; the effectiveness of methods of reducing risk exposures; the effects of war and other armed conflicts or acts of terrorism and the effects of catastrophic events including, but not limited to, hurricanes, tornadoes, earthquakes, fires, droughts and floods. Comerica cautions that the foregoing list of factors is not exclusive. For discussion of factors that may cause actual results to differ from expectations, please refer to our filings with the Securities and Exchange Commission (SEC). In particular, please refer to Item 1A. Risk Factors beginning on page 16 of Comerica's Annual Report on Form 10-K for the year ended December 31, 2010. Forward-looking statements speak only as of the date they are made. Comerica does not undertake to update forward-looking statements to reflect facts, circumstances, assumptions or events that occur after the date the forward-looking statements are made. For any forward-looking statements made in this news release or in any documents, Comerica claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

-more-

---

**COMERICA REPORTS SECOND QUARTER 2011 NET INCOME OF \$96 MILLION 12****Additional Information for Shareholders**

In connection with the proposed merger transaction, Comerica has filed with the SEC a Registration Statement on Form S-4 that includes a Proxy Statement of Sterling and a Prospectus of Comerica, and Sterling mailed the definitive Proxy Statement/Prospectus to its shareholders on or about April 6, 2011. Each of Comerica and Sterling may file other relevant documents concerning the proposed transaction.

SHAREHOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT AND THE DEFINITIVE PROXY STATEMENT/PROSPECTUS REGARDING THE MERGER AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, BECAUSE THEY CONTAIN IMPORTANT INFORMATION.

A free copy of the definitive Proxy Statement/Prospectus, as well as other filings containing information about Comerica and Sterling, may be obtained at the SEC's Internet site (<http://www.sec.gov>). You may be able to obtain these documents, free of charge, from Comerica at [www.comerica.com](http://www.comerica.com) under the tab "Investor Relations" and then under the heading "SEC Filings" or from Sterling by accessing Sterling's website at [www.banksterling.com](http://www.banksterling.com) under the tab "Investor Relations" and then under the heading "SEC Filings".

<b>Media Contact:</b>	<b>Investor Contacts:</b>
Wayne J. Mielke	Darlene P. Persons
(214) 462-4463	(214) 462-6831
	Tracy Fralick
	(214) 462-6834

**CONSOLIDATED FINANCIAL HIGHLIGHTS (unaudited)***Comerica Incorporated and Subsidiaries*

(in millions, except per share data)	June 30, 2011	Three Months Ended March 31, 2011	June 30, 2010	Six Months Ended June 30, 2011	2010
<b>PER COMMON SHARE AND COMMON STOCK DATA</b>					
Diluted net income (loss)	\$ 0.53	\$ 0.57	\$ 0.39	\$ 1.10	\$ (0.01)
Cash dividends declared	0.10	0.10	0.05	0.20	0.10
Common shareholders' equity (at period end)	34.15	33.25	32.85		
Average diluted shares (in thousands)	177,602	178,425	178,432	178,011	165,100
<b>KEY RATIOS</b>					
Return on average common shareholders' equity	6.41%	7.08%	4.89%	6.74%	(0.05)%
Return on average assets	0.70	0.77	0.50	0.73	0.43
Tier 1 common capital ratio (a) (b)	10.53	10.35	9.81		
Tier 1 risk-based capital ratio (b)	10.53	10.35	10.64		
Total risk-based capital ratio (b)	14.81	14.80	15.03		
Leverage ratio (b)	11.39	11.37	11.36		
Tangible common equity ratio (a)	10.90	10.43	10.11		
<b>AVERAGE BALANCES</b>					
Commercial loans	\$ 21,677	\$ 21,496	\$ 20,910	\$ 21,586	\$ 20,961
Real estate construction loans:					
Commercial Real Estate business line (c)	1,486	1,754	2,537	1,619	2,726
Other business lines (d)	395	425	450	410	459
Commercial mortgage loans:					
Commercial Real Estate business line (c)	1,912	1,978	1,947	1,945	1,896
Other business lines (d)	7,724	7,812	8,425	7,768	8,484
Residential mortgage loans	1,525	1,599	1,607	1,562	1,620
Consumer loans	2,243	2,281	2,448	2,262	2,464
Lease financing	958	987	1,108	972	1,119
International loans	1,254	1,219	1,240	1,237	1,261
Total loans	39,174	39,551	40,672	39,361	40,990
Earning assets	50,136	49,347	51,835	49,743	52,385
Total assets	54,517	53,775	56,258	54,148	56,885
Noninterest-bearing deposits	15,786	15,459	15,218	15,623	14,923
Interest-bearing core deposits	25,281	24,727	23,710	25,005	23,165
Total core deposits	41,067	40,186	38,928	40,628	38,088
Common shareholders' equity	5,972	5,835	5,708	5,904	5,391
Total shareholders' equity	5,972	5,835	5,708	5,904	6,283
<b>NET INTEREST INCOME</b>					
Net interest income (fully taxable equivalent basis)	\$ 392	\$ 396	\$ 424	\$ 788	\$ 840
Fully taxable equivalent adjustment	1	1	2	2	3
Net interest margin (fully taxable equivalent basis)	3.14%	3.25%	3.28%	3.19%	3.23%
<b>CREDIT QUALITY</b>					
Nonaccrual loans	\$ 941	\$ 996	\$ 1,098		
Reduced-rate loans	33	34	23		
Total nonperforming loans	974	1,030	1,121		
Foreclosed property	70	74	93		
Total nonperforming assets	1,044	1,104	1,214		

Loans past due 90 days or more and still accruing	64	72	115		
Gross loan charge-offs	125	123	158	\$ 248	\$ 342
Loan recoveries	35	22	12	57	23
Net loan charge-offs	90	101	146	191	319
Lending-related commitment charge-offs					
Total net credit-related charge-offs	90	101	146	191	319
Allowance for loan losses	806	849	967		
Allowance for credit losses on lending-related commitments	30	32	44		
Total allowance for credit losses	836	881	1,011		
Allowance for loan losses as a percentage of total loans	2.06%	2.17%	2.38%		
Net loan charge-offs as a percentage of average total loans	0.92	1.03	1.44	0.97%	1.56%
Net credit-related charge-offs as a percentage of average total loans	0.92	1.03	1.44	0.97	1.56
Nonperforming assets as a percentage of total loans and foreclosed property	2.66	2.81	2.98		
Allowance for loan losses as a percentage of total nonperforming loans	83	82	86		

(a) See Reconciliation of Non-GAAP Financial Measures.

(b) June 30, 2011 ratios are estimated.

(c) Primarily loans to real estate investors and developers.

(d) Primarily loans secured by owner-occupied real estate.

**CONSOLIDATED BALANCE SHEETS***Comerica Incorporated and Subsidiaries*

(in millions, except share data)	June 30, 2011 (unaudited)	March 31, 2011 (unaudited)	December 31, 2010	June 30, 2010 (unaudited)
<b>ASSETS</b>				
Cash and due from banks	\$ 987	\$ 875	\$ 668	\$ 816
Interest-bearing deposits with banks	2,479	3,570	1,415	3,409
Other short-term investments	124	154	141	134
Investment securities available-for-sale	7,537	7,406	7,560	7,188
Commercial loans	22,052	21,360	22,145	21,151
Real estate construction loans	1,728	2,023	2,253	2,774
Commercial mortgage loans	9,579	9,697	9,767	10,318
Residential mortgage loans	1,491	1,550	1,619	1,606
Consumer loans	2,232	2,262	2,311	2,443
Lease financing	949	958	1,009	1,084
International loans	1,162	1,326	1,132	1,226
Total loans	39,193	39,176	40,236	40,602
Less allowance for loan losses	(806)	(849)	(901)	(967)
Net loans	38,387	38,327	39,335	39,635
Premises and equipment	641	637	630	634
Customers liability on acceptances outstanding	10	14	9	24
Accrued income and other assets	3,976	4,034	3,909	4,045
Total assets	\$ 54,141	\$ 55,017	\$ 53,667	\$ 55,885
<b>LIABILITIES AND SHAREHOLDERS</b>				
<b>EQUITY</b>				
Noninterest-bearing deposits	\$ 16,344	\$ 16,357	\$ 15,538	\$ 15,769
Money market and NOW deposits	18,033	17,888	17,622	16,062
Savings deposits	1,462	1,457	1,397	1,407
Customer certificates of deposit	5,551	5,672	5,482	5,893
Other time deposits				165
Foreign office time deposits	368	499	432	484
Total interest-bearing deposits	25,414	25,516	24,933	24,011
Total deposits	41,758	41,873	40,471	39,780
Short-term borrowings	67	61	130	200
Acceptances outstanding	10	14	9	24
Accrued expenses and other liabilities	1,062	1,076	1,126	1,048
Medium- and long-term debt	5,206	6,116	6,138	9,041
Total liabilities	48,103	49,140	47,874	50,093
Common stock - \$5 par value:				
Authorized - 325,000,000 shares				
Issued - 203,878,110 shares	1,019	1,019	1,019	1,019
Capital surplus	1,472	1,464	1,481	1,467
Accumulated other comprehensive loss	(308)	(382)	(389)	(240)
Retained earnings	5,395	5,317	5,247	5,124
Less cost of common stock in treasury - 27,092,427 shares at 6/30/11, 27,103,941 shares at 3/31/11, 27,342,518 shares at 12/31/10, and 27,561,412 shares at 6/30/10	(1,540)	(1,541)	(1,565)	(1,578)
Total shareholders equity	6,038	5,877	5,793	5,792



Edgar Filing: BIOGEN IDEC INC. - Form 10-Q

Total liabilities and shareholders' equity	\$	54,141	\$	55,017	\$	53,667	\$	55,885
--	----	--------	----	--------	----	--------	----	--------

**CONSOLIDATED STATEMENTS OF INCOME (unaudited)***Comerica Incorporated and Subsidiaries*

(in millions, except per share data)	Three Months Ended June 30,		Six Months Ended June 30,	
	2011	2010	2011	2010
<b>INTEREST INCOME</b>				
Interest and fees on loans	\$ 369	\$ 412	\$ 744	\$ 824
Interest on investment securities	59	61	116	122
Interest on short-term investments	3	3	5	6
Total interest income	431	476	865	952
<b>INTEREST EXPENSE</b>				
Interest on deposits	23	29	45	64
Interest on medium- and long-term debt	17	25	34	51
Total interest expense	40	54	79	115
Net interest income	391	422	786	837
Provision for loan losses	47	126	96	301
Net interest income after provision for loan losses	344	296	690	536
<b>NONINTEREST INCOME</b>				
Service charges on deposit accounts	51	52	103	108
Fiduciary income	39	38	78	77
Commercial lending fees	21	22	42	44
Letter of credit fees	18	19	36	37
Card fees	15	15	30	28
Foreign exchange income	10	10	19	20
Bank-owned life insurance	9	9	17	17
Brokerage fees	6	6	12	12
Net securities gains	4	1	6	3
Other noninterest income	29	22	66	42
Total noninterest income	202	194	409	388
<b>NONINTEREST EXPENSES</b>				
Salaries	185	179	373	348
Employee benefits	50	45	100	89
Total salaries and employee benefits	235	224	473	437
Net occupancy expense	38	39	78	80
Equipment expense	17	15	32	32
Outside processing fee expense	25	23	49	46
Software expense	20	22	43	44
FDIC insurance expense	12	16	27	33
Legal fees	8	9	17	17
Advertising expense	7	7	14	15
Other real estate expense	6	5	14	17
Litigation and operational losses	5	2	8	3
Merger and restructuring charges	5		5	
Provision for credit losses on lending-related commitments	(2)		(5)	7
Other noninterest expenses	33	35	69	70
Total noninterest expenses	409	397	824	801
Income from continuing operations before income taxes	137	93	275	123
Provision for income taxes	41	23	76	18

Edgar Filing: BIOGEN IDEC INC. - Form 10-Q

Income from continuing operations	96	70	199	105
Income from discontinued operations, net of tax				17
<b>NET INCOME</b>	<b>96</b>	<b>70</b>	<b>199</b>	<b>122</b>
Less:				
Preferred stock dividends				123
Income allocated to participating securities	1	1	2	
<b>Net income (loss) attributable to common shares</b>	<b>\$ 95</b>	<b>\$ 69</b>	<b>\$ 197</b>	<b>\$ (1)</b>
Basic earnings per common share:				
Income (loss) from continuing operations	\$ 0.54	\$ 0.40	\$ 1.12	\$ (0.11)
Net income (loss)	0.54	0.40	1.12	(0.01)
Diluted earnings per common share:				
Income (loss) from continuing operations	0.53	0.39	1.10	(0.11)
Net income (loss)	0.53	0.39	1.10	(0.01)
Cash dividends declared on common stock	18	8	35	18
Cash dividends declared per common share	0.10	0.05	0.20	0.10

**CONSOLIDATED QUARTERLY STATEMENTS OF INCOME (unaudited)***Comerica Incorporated and Subsidiaries*

(in millions, except per share data)	Second Quarter 2011	First Quarter 2011	Fourth Quarter 2010	Third Quarter 2010	Second Quarter 2010	Second Quarter 2011 Compared To: First Quarter 2011 Amount Percent	Second Quarter 2010 Amount Percent
<b>INTEREST INCOME</b>							
Interest and fees on loans	\$ 369	\$ 375	\$ 394	\$ 399	\$ 412	\$ (6) (1)%	\$ (43) (10)%
Interest on investment securities	59	57	49	55	61	2 2	(2) (4)
Interest on short-term investments	3	2	2	2	3	1 9	(12)
Total interest income	431	434	445	456	476	(3) (1)	(45) (9)
<b>INTEREST EXPENSE</b>							
Interest on deposits	23	22	24	27	29	1 (1)	(6) (21)
Interest on short-term borrowings			1				(46) (77)
Interest on medium- and long-term debt	17	17	15	25	25	4	(8) (30)
Total interest expense	40	39	40	52	54	1 1	(14) (25)
Net interest income	391	395	405	404	422	(4) (1)	(31) (7)
Provision for loan losses	47	49	57	122	126	(2) (4)	(79) (63)
Net interest income after provision for loan losses	344	346	348	282	296	(2) (1)	48 16
<b>NONINTEREST INCOME</b>							
Service charges on deposit accounts	51	52	49	51	52	(1) (4)	(1) (5)
Fiduciary income	39	39	39	38	38	2	1 3
Commercial lending fees	21	21	29	22	22	4	(1) (1)
Letter of credit fees	18	18	20	19	19	(1)	(1) (1)
Card fees	15	15	15	15	15	7	6
Foreign exchange income	10	9	11	8	10	1 7	(4)
Bank-owned life insurance	9	8	14	9	9	1 1	1
Brokerage fees	6	6	7	6	6	(8)	(8)
Net securities gains	4	2			1	2 82	3 N/M
Other noninterest income	29	37	31	18	22	(8) (20)	7 32
Total noninterest income	202	207	215	186	194	(5) (2)	8 4
<b>NONINTEREST EXPENSES</b>							
Salaries	185	188	205	187	179	(3) (1)	6 3
Employee benefits	50	50	43	47	45	(1)	5 11
Total salaries and employee benefits	235	238	248	234	224	(3) (1)	11 5
Net occupancy expense	38	40	42	40	39	(2) (3)	(1)
Equipment expense	17	15	16	15	15	2 5	2 5
Outside processing fee expense	25	24	27	23	23	1 5	2 8
Software expense	20	23	23	22	22	(3) (8)	(2) (4)
FDIC insurance expense	12	15	15	14	16	(3) (16)	(4) (24)
Legal fees	8	9	9	9	9	(1)	(1)
Advertising expense	7	7	8	7	7		(5)
Other real estate expense	6	8	5	7	5	(2) (35)	1 9
Litigation and operational losses	5	3	6	2	2	2 60	3 N/M
Merger and restructuring charges	5					5 N/M	5 N/M
Provision for credit losses on lending-related commitments	(2)	(3)	(3)	(6)		1 21	(2) N/M
Other noninterest expenses	33	36	41	35	35	(3) (11)	(2) (8)
Total noninterest expenses	409	415	437	402	397	(6) (1)	12 3
Income before income taxes	137	138	126	66	93	(1) (1)	44 48
Provision for income taxes	41	35	30	7	23	6 19	18 81
<b>NET INCOME</b>	96	103	96	59	70	(7) (7)	26 37
<b>Less:</b>							
Income allocated to participating securities	1	1	1		1	(6)	N/M

# Edgar Filing: BIOGEN IDEC INC. - Form 10-Q

<b>Net income (loss) attributable to common shares</b>	\$	95	\$	102	\$	95	\$	59	\$	69	\$	(7)	(7)%	\$	26	36%
Earnings per common share:																
Basic	\$	0.54	\$	0.58	\$	0.54	\$	0.34	\$	0.40	\$	(0.04)	(7)%	\$	0.14	35%
Diluted		0.53		0.57		0.53		0.33		0.39		(0.04)	(7)		0.14	36
Cash dividends declared on common stock		18		17		18		9		8		1			10	N/M
Cash dividends declared per common share		0.10		0.10		0.10		0.05		0.05					0.05	N/M

---

N/M - Not meaningful

**ANALYSIS OF THE ALLOWANCE FOR LOAN LOSSES (unaudited)**
*Comerica Incorporated and Subsidiaries*

(in millions)	2011 2nd Qtr	1st Qtr	4th Qtr	2010 3rd Qtr	2nd Qtr
Balance at beginning of period	\$ 849	\$ 901	\$ 957	\$ 967	\$ 987
Loan charge-offs:					
Commercial	66	65	43	38	65
Real estate construction:					
Commercial Real Estate business line (a)	12	8	34	40	30
Other business lines (b)		1		1	
Total real estate construction	12	9	34	41	30
Commercial mortgage:					
Commercial Real Estate business line (a)	8	9	9	16	12
Other business lines (b)	23	25	34	40	36
Total commercial mortgage	31	34	43	56	48
Residential mortgage	7	2	5	2	5
Consumer	9	8	15	7	9
Lease financing					1
International		5		1	
Total loan charge-offs	125	123	140	145	158
Recoveries on loans previously charged-off:					
Commercial	13	4	7	7	4
Real estate construction	5	2	3	1	6
Commercial mortgage	5	9	10	2	1
Residential mortgage	1		1		
Consumer	1	1	2	1	1
Lease financing	6	5	4	1	
International	4	1		1	
Total recoveries	35	22	27	13	12
Net loan charge-offs	90	101	113	132	146
Provision for loan losses	47	49	57	122	126
Balance at end of period	\$ 806	\$ 849	\$ 901	\$ 957	\$ 967
Allowance for loan losses as a percentage of total loans	2.06%	2.17%	2.24%	2.38%	2.38%
Net loan charge-offs as a percentage of average total loans	0.92	1.03	1.13	1.32	1.44
Net credit-related charge-offs as a percentage of average total loans	0.92	1.03	1.13	1.32	1.44

(a) Primarily charge-offs of loans to real estate investors and developers.

(b) Primarily charge-offs of loans secured by owner-occupied real estate.

**ANALYSIS OF THE ALLOWANCE FOR CREDIT LOSSES ON LENDING-RELATED COMMITMENTS (unaudited)**

# Edgar Filing: BIOGEN IDEC INC. - Form 10-Q

*Comerica Incorporated and Subsidiaries*

(in millions)	2011 2nd Qtr	1st Qtr	4th Qtr	2010 3rd Qtr	2nd Qtr
Balance at beginning of period	\$ 32	\$ 35	\$ 38	\$ 44	\$ 44
Add: Provision for credit losses on lending-related commitments	(2)	(3)	(3)	(6)	
Balance at end of period	\$ 30	\$ 32	\$ 35	\$ 38	\$ 44
Unfunded lending-related commitments sold	\$ 3	\$ 2	\$	\$	\$ 2

**NONPERFORMING ASSETS (unaudited)**
*Comerica Incorporated and Subsidiaries*

(in millions)	2011			2010		
	2nd Qtr	1st Qtr	4th Qtr	3rd Qtr	2nd Qtr	
SUMMARY OF NONPERFORMING ASSETS AND PAST DUE LOANS						
Nonaccrual loans:						
Business loans:						
Commercial	\$ 261	\$ 226	\$ 252	\$ 258	\$ 239	
Real estate construction:						
Commercial Real Estate business line (a)	137	195	259	362	385	
Other business lines (b)	2	3	4	4	4	
Total real estate construction	139	198	263	366	389	
Commercial mortgage:						
Commercial Real Estate business line (a)	186	197	181	153	135	
Other business lines (b)	269	293	302	304	257	
Total commercial mortgage	455	490	483	457	392	
Lease financing	6	7	7	10	11	
International	7	4	2	2	3	
Total nonaccrual business loans	868	925	1,007	1,093	1,034	
Retail loans:						
Residential mortgage	60	58	55	59	53	
Consumer:						
Home equity	4	6	5	5	7	
Other consumer	9	7	13	6	4	
Total consumer	13	13	18	11	11	
Total nonaccrual retail loans	73	71	73	70	64	
Total nonaccrual loans	941	996	1,080	1,163	1,098	
Reduced-rate loans	33	34	43	28	23	
Total nonperforming loans	974	1,030	1,123	1,191	1,121	
Foreclosed property	70	74	112	120	93	
Total nonperforming assets	\$ 1,044	\$ 1,104	\$ 1,235	\$ 1,311	\$ 1,214	
Nonperforming loans as a percentage of total loans						
	2.49%	2.63%	2.79%	2.96%	2.76%	
Nonperforming assets as a percentage of total loans and foreclosed property						
	2.66	2.81	3.06	3.24	2.98	
Allowance for loan losses as a percentage of total nonperforming loans						
	83	82	80	80	86	
Loans past due 90 days or more and still accruing	\$ 64	\$ 72	\$ 62	\$ 104	\$ 115	
ANALYSIS OF NONACCRUAL LOANS						
Nonaccrual loans at beginning of period	\$ 996	\$ 1,080	\$ 1,163	\$ 1,098	\$ 1,145	
Loans transferred to nonaccrual (c)	163	166	180	294	199	
Nonaccrual business loan gross charge-offs (d)	(109)	(111)	(120)	(136)	(143)	
Loans transferred to accrual status (c)		(4)	(4)	(10)		
Nonaccrual business loans sold (e)	(9)	(60)	(41)	(12)	(47)	
Payments/Other (f)	(100)	(75)	(98)	(71)	(56)	
Nonaccrual loans at end of period	\$ 941	\$ 996	\$ 1,080	\$ 1,163	\$ 1,098	

(a) Primarily loans to real estate investors and developers.



## Edgar Filing: BIOGEN IDEC INC. - Form 10-Q

(b) Primarily loans secured by owner-occupied real estate.

(c) Based on an analysis of nonaccrual loans with book balances greater than \$2 million.

(d) Analysis of gross loan charge-offs:

Nonaccrual business loans	\$	109	\$	111	\$	120	\$	136	\$	143
Performing watch list loans				2						1
Consumer and residential mortgage loans		16		10		20		9		14
Total gross loan charge-offs	\$	125	\$	123	\$	140	\$	145	\$	158

(e) Analysis of loans sold:

Nonaccrual business loans	\$	9	\$	60	\$	41	\$	12	\$	47
Performing watch list loans		6		35		29		7		15
Total loans sold	\$	15	\$	95	\$	70	\$	19	\$	62

(f) Includes net changes related to nonaccrual loans with balances less than \$2 million, payments on nonaccrual loans with book balances greater than \$2 million and transfers of nonaccrual loans to foreclosed property. Excludes business loan gross charge-offs and business nonaccrual loans sold.

**ANALYSIS OF NET INTEREST INCOME (FTE) (unaudited)**
*Comerica Incorporated and Subsidiaries*

(dollar amounts in millions)	June 30, 2011		Six Months Ended		June 30, 2010	
	Average Balance	Interest	Average Rate	Average Balance	Interest	Average Rate
Commercial loans	\$ 21,586	\$ 396	3.70%	\$ 20,961	\$ 411	3.95%
Real estate construction loans	2,029	36	3.62	3,185	48	3.03
Commercial mortgage loans	9,713	191	3.96	10,380	216	4.19
Residential mortgage loans	1,562	42	5.37	1,620	44	5.43
Consumer loans	2,262	39	3.42	2,464	44	3.57
Lease financing	972	17	3.56	1,119	21	3.73
International loans	1,237	24	3.83	1,261	25	4.00
Business loan swap income		1			17	
Total loans	39,361	746	3.82	40,990	826	4.06
Auction-rate securities available-for-sale	527	2	0.80	847	5	1.06
Other investment securities available-for-sale	6,832	114	3.39	6,475	118	3.72
Total investment securities available-for-sale	7,359	116	3.19	7,322	123	3.40
Federal funds sold and securities purchased under agreements to resell	2		0.32	1		1.17
Interest-bearing deposits with banks (a)	2,897	4	0.25	3,944	5	0.25
Other short-term investments	124	1	2.05	128	1	1.70
Total earning assets	49,743	867	3.51	52,385	955	3.67
Cash and due from banks	878			792		
Allowance for loan losses	(883)			(1,048)		
Accrued income and other assets	4,410			4,756		
Total assets	\$ 54,148			\$ 56,885		
Money market and NOW deposits	\$ 18,003	23	0.26	\$ 15,709	25	0.32
Savings deposits	1,443	1	0.09	1,407		0.07
Customer certificates of deposit	5,559	20	0.73	6,049	30	0.97
Total interest-bearing core deposits	25,005	44	0.36	23,165	55	0.48
Other time deposits				584	9	3.18
Foreign office time deposits	413	1	0.50	453		0.22
Total interest-bearing deposits	25,418	45	0.36	24,202	64	0.54
Short-term borrowings	103		0.21	241		0.19
Medium- and long-term debt	5,974	34	1.15	10,169	51	0.99
Total interest-bearing sources	31,495	79	0.51	34,612	115	0.67
Noninterest-bearing deposits	15,623			14,923		
Accrued expenses and other liabilities	1,126			1,067		
Total shareholders' equity	5,904			6,283		
Total liabilities and shareholders' equity	\$ 54,148			\$ 56,885		
Net interest income/rate spread (FTE)		\$ 788	3.00		\$ 840	3.00
FTE adjustment		\$ 2			\$ 3	
			0.19			0.23

## Edgar Filing: BIOGEN IDEC INC. - Form 10-Q

Impact of net noninterest-bearing sources of funds

Net interest margin (as a percentage of average earning assets) (FTE) (a)

3.19%

3.23%

- 
- (a) Excess liquidity, represented by average balances deposited with the Federal Reserve Bank, reduced the net interest margin by 18 basis points and 24 basis points year-to-date in 2011 and 2010, respectively. Excluding excess liquidity, the net interest margin would have been 3.37% in 2011 and 3.47% in 2010. See Reconciliation of Non-GAAP Financial Measures.

**ANALYSIS OF NET INTEREST INCOME (FTE) (unaudited)**
*Comerica Incorporated and Subsidiaries*

(dollar amounts in millions)	June 30, 2011			Three Months Ended March 31, 2011			June 30, 2010		
	Average Balance	Interest	Average Rate	Average Balance	Interest	Average Rate	Average Balance	Interest	Average Rate
Commercial loans	\$ 21,677	\$ 196	3.65%	\$ 21,496	\$ 200	3.76%	\$ 20,910	\$ 206	3.95%
Real estate construction loans	1,881	17	3.75	2,179	19	3.51	2,987	23	3.13
Commercial mortgage loans	9,636	96	3.98	9,790	95	3.95	10,372	109	4.20
Residential mortgage loans	1,525	21	5.50	1,599	21	5.24	1,607	22	5.44
Consumer loans	2,243	20	3.42	2,281	19	3.42	2,448	22	3.56
Lease financing	958	8	3.50	987	9	3.62	1,108	10	3.72
International loans	1,254	12	3.80	1,219	12	3.87	1,240	13	4.07
Business loan swap income					1			9	
Total loans	39,174	370	3.79	39,551	376	3.85	40,672	414	4.07
Auction-rate securities available-for-sale	500	1	0.71	554	1	0.88	816	3	1.19
Other investment securities available-for-sale	6,907	58	3.40	6,757	56	3.37	6,446	58	3.71
Total investment securities available-for-sale	7,407	59	3.20	7,311	57	3.17	7,262	61	3.41
Federal funds sold and securities purchased under agreements to resell	2		0.33	3		0.32	1		1.35
Interest-bearing deposits with banks (a)	3,433	3	0.25	2,354	1	0.26	3,768	3	0.25
Other short-term investments	120		1.39	128	1	2.68	132		1.65
Total earning assets	50,136	432	3.46	49,347	435	3.57	51,835	478	3.70
Cash and due from banks	872			884			795		
Allowance for loan losses	(859)			(908)			(1,037)		
Accrued income and other assets	4,368			4,452			4,665		
Total assets	\$ 54,517			\$ 53,775			\$ 56,258		
Money market and NOW deposits	\$ 18,207	11	0.26	\$ 17,797	12	0.26	\$ 16,354	13	0.32
Savings deposits	1,465	1	0.09	1,421		0.09	1,429		0.07
Customer certificates of deposit	5,609	10	0.70	5,509	10	0.76	5,927	15	0.92
Total interest-bearing core deposits	25,281	22	0.35	24,727	22	0.36	23,710	28	0.45
Other time deposits							295	1	2.14
Foreign office time deposits	413	1	0.52	412		0.49	448		0.23
Total interest-bearing deposits	25,694	23	0.35	25,139	22	0.37	24,453	29	0.47
Short-term borrowings	112		0.14	94		0.31	248		0.27
Medium- and long-term debt	5,821	17	1.20	6,128	17	1.10	9,571	25	1.04
Total interest-bearing sources	31,627	40	0.51	31,361	39	0.51	34,272	54	0.63
Noninterest-bearing deposits	15,786			15,459			15,218		
Accrued expenses and other liabilities	1,132			1,120			1,060		
Total shareholders' equity	5,972			5,835			5,708		
Total liabilities and shareholders' equity	\$ 54,517			\$ 53,775			\$ 56,258		
Net interest income/rate spread (FTE)		\$ 392	2.95		\$ 396	3.06		\$ 424	3.07
FTE adjustment		\$ 1			\$ 1			\$ 2	

## Edgar Filing: BIOGEN IDEC INC. - Form 10-Q

Impact of net noninterest-bearing sources of funds	0.19	0.19	0.21
Net interest margin (as a percentage of average earning assets) (FTE) (a)	3.14%	3.25%	3.28%

- 
- (a) Excess liquidity, represented by average balances deposited with the Federal Reserve Bank, reduced the net interest margin by 21 basis points and by 14 points in the second and first quarters of 2011, respectively and by 23 basis points in the second quarter of 2010. Excluding excess liquidity, the net interest margin would have been 3.35%, 3.39% and 3.51% in each respective period. See Reconciliation of Non-GAAP Financial Measures.

**CONSOLIDATED STATISTICAL DATA (unaudited)***Comerica Incorporated and Subsidiaries*

(in millions, except per share data)	June 30, 2011	March 31, 2011	December 31, 2010	September 30, 2010	June 30, 2010
<b>Commercial loans:</b>					
Floor plan	\$ 1,478	\$ 1,893	\$ 2,017	\$ 1,693	\$ 1,586
Other	20,574	19,467	20,128	19,739	19,565
Total commercial loans	22,052	21,360	22,145	21,432	21,151
<b>Real estate construction loans:</b>					
Commercial Real Estate business line (a)	1,343	1,606	1,826	2,023	2,345
Other business lines (b)	385	417	427	421	429
Total real estate construction loans	1,728	2,023	2,253	2,444	2,774
<b>Commercial mortgage loans:</b>					
Commercial Real Estate business line (a)	1,930	1,918	1,937	2,091	2,035
Other business lines (b)	7,649	7,779	7,830	8,089	8,283
Total commercial mortgage loans	9,579	9,697	9,767	10,180	10,318
Residential mortgage loans	1,491	1,550	1,619	1,586	1,606
<b>Consumer loans:</b>					
Home equity	1,622	1,661	1,704	1,736	1,761
Other consumer	610	601	607	667	682
Total consumer loans	2,232	2,262	2,311	2,403	2,443
Lease financing	949	958	1,009	1,053	1,084
International loans	1,162	1,326	1,132	1,182	1,226
Total loans	\$ 39,193	\$ 39,176	\$ 40,236	\$ 40,280	\$ 40,602
Goodwill	\$ 150	\$ 150	\$ 150	\$ 150	\$ 150
Loan servicing rights	4	4	5	5	6
Tier 1 common capital ratio (c) (d)	10.53%	10.35%	10.13%	9.96%	9.81%
Tier 1 risk-based capital ratio (d)	10.53	10.35	10.13	9.96	10.64
Total risk-based capital ratio (d)	14.81	14.80	14.54	14.37	15.03
Leverage ratio (d)	11.39	11.37	11.26	10.91	11.36
Tangible common equity ratio (c)	10.90	10.43	10.54	10.39	10.11
Book value per common share	\$ 34.15	\$ 33.25	\$ 32.82	\$ 33.19	\$ 32.85
<b>Market value per share for the quarter:</b>					
High	39.00	43.53	43.44	40.21	45.85
Low	33.08	36.20	34.43	33.11	35.44
Close	34.57	36.72	42.24	37.15	36.83
<b>Quarterly ratios:</b>					
Return on average common shareholders equity	6.41%	7.08%	6.53%	4.07%	4.89%
Return on average assets	0.70	0.77	0.71	0.43	0.50
Efficiency ratio	69.33	69.05	70.38	67.88	64.47
Number of banking centers	446	445	444	441	437
Number of employees - full time equivalent	8,915	8,955	9,001	9,075	9,107

(a) Primarily loans to real estate investors and developers.

- (b) Primarily loans secured by owner-occupied real estate.
- (c) See Reconciliation of Non-GAAP Financial Measures.
- (d) June 30, 2011 ratios are estimated.

**PARENT COMPANY ONLY BALANCE SHEETS (unaudited)***Comerica Incorporated*

(in millions, except share data)	June 30, 2011	December 31, 2010	June 30, 2010
<b>ASSETS</b>			
Cash and due from subsidiary bank	\$ 14	\$	\$ 15
Short-term investments with subsidiary bank	413	327	659
Other short-term investments	90	86	83
Investment in subsidiaries, principally banks	6,122	5,957	5,961
Premises and equipment	3	4	4
Other assets	162	181	190
Total assets	\$ 6,804	\$ 6,555	\$ 6,912
<b>LIABILITIES AND SHAREHOLDERS' EQUITY</b>			
Medium- and long-term debt	\$ 635	\$ 635	\$ 999
Other liabilities	131	127	121
Total liabilities	766	762	1,120
Common stock - \$5 par value:			
Authorized - 325,000,000 shares			
Issued - 203,878,110 shares	1,019	1,019	1,019
Capital surplus	1,472	1,481	1,467
Accumulated other comprehensive loss	(308)	(389)	(240)
Retained earnings	5,395	5,247	5,124
Less cost of common stock in treasury - 27,092,427 shares at 6/30/11, 27,342,518 shares at 12/31/10, and 27,561,412 shares at 6/30/10	(1,540)	(1,565)	(1,578)
Total shareholders' equity	6,038	5,793	5,792
Total liabilities and shareholders' equity	\$ 6,804	\$ 6,555	\$ 6,912

**CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (unaudited)***Comerica Incorporated and Subsidiaries*

(in millions, except per share data)	Preferred Stock	Common Stock Shares Outstanding	Common Stock Amount	Capital Surplus	Accumulated Other Comprehensive Loss	Retained Earnings	Treasury Stock	Total Shareholders' Equity
<b>BALANCE AT DECEMBER 31, 2009</b>	\$ 2,151	151.2	\$ 894	\$ 740	\$ (336)	\$ 5,161	\$ (1,581)	\$ 7,029
Net income						122		122
Other comprehensive income, net of tax					96			96
Total comprehensive income								218
Cash dividends declared on preferred stock						(38)		(38)
Cash dividends declared on common stock (\$0.10 per share)						(18)		(18)
Purchase of common stock							(4)	(4)
Issuance of common stock		25.1	125	724				849
Redemption of preferred stock	(2,250)							(2,250)



# Edgar Filing: BIOGEN IDEC INC. - Form 10-Q

Redemption discount accretion on preferred stock	94						(94)							
Accretion of discount on preferred stock	5						(5)							
Net issuance of common stock under employee stock plans					(5)		(4)		6					(3)
Share-based compensation					11									11
Other					(3)				1					(2)
<b>BALANCE AT JUNE 30, 2010</b>	\$	176.3	\$	1,019	\$	1,467	\$	(240)	\$	5,124	\$	(1,578)	\$	5,792
<b>BALANCE AT DECEMBER 31, 2010</b>	\$	176.5	\$	1,019	\$	1,481	\$	(389)	\$	5,247	\$	(1,565)	\$	5,793
Net income									199					199
Other comprehensive income, net of tax							81							81
Total comprehensive income														280
Cash dividends declared on common stock (\$0.20 per share)									(35)					(35)
Purchase of common stock		(0.5)										(21)		(21)
Net issuance of common stock under employee stock plans		0.8				(30)			(16)		46			
Share-based compensation						21								21
<b>BALANCE AT JUNE 30, 2011</b>	\$	176.8	\$	1,019	\$	1,472	\$	(308)	\$	5,395	\$	(1,540)	\$	6,038

**BUSINESS SEGMENT FINANCIAL RESULTS (unaudited)**
*Comerica Incorporated and Subsidiaries*

(dollar amounts in millions) Three Months Ended June 30, 2011	Business Bank	Retail Bank	Wealth Management	Finance	Other	Total
Earnings summary:						
Net interest income (expense) (FTE)	\$ 342	\$ 141	\$ 48	\$ (147)	\$ 8	\$ 392
Provision for loan losses	6	24	14		3	47
Noninterest income	79	46	63	11	3	202
Noninterest expenses	158	162	76	3	10	409
Provision (benefit) for income taxes (FTE)	81	4	9	(52)		42
Net income (loss)	\$ 176	\$ (3)	\$ 12	\$ (87)	\$ (2)	\$ 96
Net credit-related charge-offs	\$ 54	\$ 22	\$ 14	\$	\$	\$ 90
Selected average balances:						
Assets	\$ 29,893	\$ 5,453	\$ 4,728	\$ 9,406	\$ 5,037	\$ 54,517
Loans	29,380	4,999	4,742	48	5	39,174
Deposits	20,396	17,737	2,978	239	130	41,480
Statistical data:						
Return on average assets (a)	2.35%	(0.06)%	1.03%	N/M	N/M	0.70%
Net interest margin (b)	4.65	3.22	4.07	N/M	N/M	3.14
Efficiency ratio	37.41	86.48	71.40	N/M	N/M	69.33

Three Months Ended March 31, 2011	Business Bank	Retail Bank	Wealth Management	Finance	Other	Total
Earnings summary:						
Net interest income (expense) (FTE)	\$ 341	\$ 139	\$ 44	\$ (135)	\$ 7	\$ 396
Provision for loan losses	18	23	8			49
Noninterest income	77	42	64	16	8	207
Noninterest expenses	160	162	78	3	12	415
Provision (benefit) for income taxes (FTE)	73	(2)	8	(46)	3	36
Net income (loss)	\$ 167	\$ (2)	\$ 14	\$ (76)	\$	\$ 103
Net credit-related charge-offs	\$ 73	\$ 23	\$ 5	\$	\$	\$ 101
Selected average balances:						
Assets	\$ 30,091	\$ 5,558	\$ 4,809	\$ 9,314	\$ 4,003	\$ 53,775
Loans	29,609	5,106	4,807	22	7	39,551
Deposits	20,084	17,360	2,800	249	105	40,598
Statistical data:						
Return on average assets (a)	2.22%	(0.05)%	1.14%	N/M	N/M	0.77%
Net interest margin (b)	4.66	3.25	3.76	N/M	N/M	3.25
Efficiency ratio	38.14	89.19	74.38	N/M	N/M	69.05

Three Months Ended June 30, 2010	Business Bank	Retail Bank	Wealth Management	Finance	Other	Total
Earnings summary:						
Net interest income (expense) (FTE)	\$ 351	\$ 134	\$ 45	\$ (103)	\$ (3)	\$ 424
Provision for loan losses	83	20	19		4	126
Noninterest income	78	42	61	13		194
Noninterest expenses	157	160	79	2	(1)	397

# Edgar Filing: BIOGEN IDEC INC. - Form 10-Q

Provision (benefit) for income taxes (FTE)	54	(1)	3	(35)	4	25
Net income (loss)	\$ 135	\$ (3)	\$ 5	\$ (57)	\$ (10)	\$ 70
Net credit-related charge-offs	\$ 113	\$ 22	\$ 11	\$	\$	146
Selected average balances:						
Assets	\$ 30,609	\$ 5,937	\$ 4,903	\$ 9,343	\$ 5,466	\$ 56,258
Loans	30,353	5,446	4,840	36	(3)	40,672
Deposits	19,069	16,930	2,924	653	95	39,671
Statistical data:						
Return on average assets (a)	1.75%	(0.06)%	0.43%	N/M	N/M	0.50%
Net interest margin (b)	4.63	3.17	3.73	N/M	N/M	3.28
Efficiency ratio	36.92	89.14	77.57	N/M	N/M	64.47

(a) Return on average assets is calculated based on the greater of average assets or average liabilities and attributed equity.

(b) Net interest margin is calculated based on the greater of average earning assets or average deposits and purchased funds.

FTE - Fully Taxable Equivalent

N/M - Not Meaningful

**MARKET SEGMENT FINANCIAL RESULTS (unaudited)**
*Comerica Incorporated and Subsidiaries*

(dollar amounts in millions)									
Three Months Ended June 30, 2011	Midwest	Western	Texas	Florida	Other Markets	International	Finance & Other Businesses	Total	
Earnings summary:									
Net interest income (expense) (FTE)	\$ 204	\$ 166	\$ 89	\$ 12	\$ 41	\$ 19	\$ (139)	\$ 392	
Provision for loan losses	15	20	(2)	11	5	(5)	3	47	
Noninterest income	100	37	25	4	13	9	14	202	
Noninterest expenses	183	108	63	12	21	9	13	409	
Provision (benefit) for income taxes (FTE)	44	25	20	(2)	(2)	9	(52)	42	
Net income (loss)	\$ 62	\$ 50	\$ 33	\$ (5)	\$ 30	\$ 15	\$ (89)	\$ 96	
Net credit-related charge-offs (recoveries)	\$ 37	\$ 26	\$ 3	\$ 15	\$ 11	\$ (2)	\$	\$ 90	
Selected average balances:									
Assets	\$ 14,267	\$ 12,329	\$ 7,081	\$ 1,534	\$ 3,101	\$ 1,762	\$ 14,443	\$ 54,517	
Loans	14,051	12,121	6,871	1,565	2,823	1,690	53	39,174	
Deposits	18,319	12,458	6,175	396	2,451	1,312	369	41,480	
Statistical data:									
Return on average assets (a)	1.28%	1.48%	1.84%	(1.29)%	3.89%	3.33%	N/M	0.70%	
Net interest margin (b)	4.46	5.35	5.19	3.14	5.88	4.40	N/M	3.14	
Efficiency ratio	60.30	53.19	55.16	77.62	40.47	33.16	N/M	69.33	

Three Months Ended March 31, 2011	Midwest	Western	Texas	Florida	Other Markets	International	Finance & Other Businesses	Total	
Earnings summary:									
Net interest income (expense) (FTE)	\$ 203	\$ 164	\$ 87	\$ 11	\$ 41	\$ 18	\$ (128)	\$ 396	
Provision for loan losses	34	11	4	8	(7)	(1)		49	
Noninterest income	100	37	23	4	11	8	24	207	
Noninterest expenses	188	109	61	12	21	9	15	415	
Provision (benefit) for income taxes (FTE)	28	30	16	(1)		6	(43)	36	
Net income (loss)	\$ 53	\$ 51	\$ 29	\$ (4)	\$ 38	\$ 12	\$ (76)	\$ 103	
Net credit-related charge-offs	\$ 46	\$ 26	\$ 8	\$ 8	\$ 9	\$ 4	\$	\$ 101	
Selected average balances:									
Assets	\$ 14,307	\$ 12,590	\$ 7,031	\$ 1,553	\$ 3,242	\$ 1,735	\$ 13,317	\$ 53,775	
Loans	14,104	12,383	6,824	1,580	2,960	1,671	29	39,551	
Deposits	18,230	12,235	5,786	367	2,298	1,328	354	40,598	
Statistical data:									
Return on average assets (a)	1.08%	1.54%	1.65%	(0.93)%	4.70%	2.79%	N/M	0.77%	
Net interest margin (b)	4.49	5.37	5.17	2.82	5.73	4.34	N/M	3.25	
Efficiency ratio	61.99	54.36	55.39	80.08	42.38	34.62	N/M	69.05	

Three Months Ended June 30, 2010	Midwest	Western	Texas	Florida	Other Markets	International	Finance & Other Businesses	Total	
Earnings summary:									
Net interest income (expense) (FTE)	\$ 211	\$ 163	\$ 81	\$ 12	\$ 44	\$ 19	\$ (106)	\$ 424	
Provision for loan losses	34	27	(1)	17	50	(5)	4	126	
Noninterest income	97	33	23	4	15	9	13	194	
Noninterest expenses	180	110	65	12	21	8	1	397	

## Edgar Filing: BIOGEN IDEC INC. - Form 10-Q

Provision (benefit) for income taxes (FTE)		33		21		14		(5)		(16)		9		(31)		25
Net income (loss)	\$	61	\$	38	\$	26	\$	(8)	\$	4	\$	16	\$	(67)	\$	70
Net credit-related charge-offs	\$	44	\$	47	\$	8	\$	7	\$	40	\$		\$		\$	146
Selected average balances:																
Assets	\$	14,626	\$	13,006	\$	6,652	\$	1,576	\$	3,934	\$	1,655	\$	14,809	\$	56,258
Loans		14,592		12,792		6,428		1,575		3,661		1,591		33		40,672
Deposits		17,988		11,951		5,316		404		2,212		1,052		748		39,671
Statistical data:																
Return on average assets (a)		1.25%		1.15%		1.54%		(2.18)%		0.46%		3.90%		N/M		0.50%
Net interest margin (b)		4.66		5.13		5.05		2.94		4.91		4.62		N/M		3.28
Efficiency ratio		58.16		56.15		62.38		76.90		38.26		30.48		N/M		64.47

---

(a) Return on average assets is calculated based on the greater of average assets or average liabilities and attributed equity.

(b) Net interest margin is calculated based on the greater of average earning assets or average deposits and purchased funds.

FTE - Fully Taxable Equivalent

N/M - Not Meaningful

**RECONCILIATION OF NON-GAAP FINANCIAL MEASURES (unaudited) (page 1 of 2)**
*Comerica Incorporated and Subsidiaries*

(dollar amounts in millions)		Six Months Ended June 30,	
		2011	2010
<b>Impact of Excess Liquidity on Net Interest Margin (FTE):</b>			
Net interest income (FTE)	\$	788	\$ 840
Less:			
Interest earned on excess liquidity (a)		3	5
Net interest income (FTE), excluding excess liquidity	\$	785	\$ 835
Average earning assets	\$	49,743	\$ 52,385
Less:			
Average net unrealized gains on investment securities available-for-sale		48	71
Average earning assets for net interest margin (FTE)		49,695	52,314
Less:			
Excess liquidity (a)		2,843	3,905
Average earning assets for net interest margin (FTE), excluding excess liquidity	\$	46,852	\$ 48,409
Net interest margin (FTE)		3.19%	3.23%
Net interest margin (FTE), excluding excess liquidity		3.37	3.47
Impact of excess liquidity on net interest margin (FTE)		(0.18)	(0.24)

	2011		2010		
	2nd Qtr	1st Qtr	4th Qtr	3rd Qtr	2nd Qtr
<b>Impact of Excess Liquidity on Net Interest Margin (FTE):</b>					
Net interest income (FTE)	\$ 392	\$ 396	\$ 406	\$ 405	\$ 424
Less:					
Interest earned on excess liquidity (a)	2	1	1	2	2
Net interest income (FTE), excluding excess liquidity	\$ 390	\$ 395	\$ 405	\$ 403	\$ 422
Average earning assets	\$ 50,136	\$ 49,347	\$ 49,102	\$ 50,189	\$ 51,835
Less:					
Average net unrealized gains on investment securities available-for-sale	74	22	139	180	80
Average earning assets for net interest margin (FTE)	50,062	49,325	48,963	50,009	51,755
Less:					
Excess liquidity (a)	3,382	2,297	1,793	2,983	3,719
Average earning assets for net interest margin (FTE), excluding excess liquidity	\$ 46,680	\$ 47,028	\$ 47,170	\$ 47,026	\$ 48,036
Net interest margin (FTE)	3.14%	3.25%	3.29%	3.23%	3.28%
Net interest margin (FTE), excluding excess liquidity	3.35	3.39	3.41	3.42	3.51
Impact of excess liquidity on net interest margin (FTE)	(0.21)	(0.14)	(0.12)	(0.19)	(0.23)

(a) Excess liquidity represented by interest earned on and average balances deposited with the FRB.

## Edgar Filing: BIOGEN IDEC INC. - Form 10-Q

The net interest margin (FTE), excluding excess liquidity, removes interest earned on balances deposited with the FRB from net interest income (FTE) and average balances deposited with the FRB from average earning assets from the numerator and denominator of the net interest margin (FTE) ratio, respectively. Comerica believes this measurement provides meaningful information to investors, regulators, management and others of the impact on net interest income and net interest margin resulting from Comerica's short-term investment in low yielding instruments.

**RECONCILIATION OF NON-GAAP FINANCIAL MEASURES (unaudited) (page 2 of 2)***Comerica Incorporated and Subsidiaries*

	June 30, 2011	March 31, 2011	December 31, 2010	September 30, 2010	June 30, 2010
<b>Tier 1 Common Capital Ratio:</b>					
Tier 1 capital (a) (b)	\$ 6,193	\$ 6,107	\$ 6,027	\$ 5,940	\$ 6,371
Less:					
Trust preferred securities					495
Tier 1 common capital (b)	\$ 6,193	\$ 6,107	\$ 6,027	\$ 5,940	\$ 5,876
Risk-weighted assets (a) (b)	\$ 58,790	\$ 58,998	\$ 59,506	\$ 59,608	\$ 59,877
Tier 1 capital ratio (b)	10.53%	10.35%	10.13%	9.96%	10.64%
Tier 1 common capital ratio (b)	10.53	10.35	10.13	9.96	9.81
<b>Tangible Common Equity Ratio:</b>					
Total common shareholders equity	\$ 6,038	\$ 5,877	\$ 5,793	\$ 5,857	\$ 5,792
Less:					
Goodwill	150	150	150	150	150
Other intangible assets	4	5	6	6	6
Tangible common equity	\$ 5,884	\$ 5,722	\$ 5,637	\$ 5,701	\$ 5,636
Total assets	\$ 54,141	\$ 55,017	\$ 53,667	\$ 55,004	\$ 55,885
Less:					
Goodwill	150	150	150	150	150
Other intangible assets	4	5	6	6	6
Tangible assets	\$ 53,987	\$ 54,862	\$ 53,511	\$ 54,848	\$ 55,729
Common equity ratio	11.15%	10.68%	10.80%	10.65%	10.36%
Tangible common equity ratio	10.90	10.43	10.54	10.39	10.11

(a) Tier 1 capital and risk-weighted assets as defined by regulation.

(b) June 30, 2011 Tier 1 capital and risk-weighted assets are estimated.

The Tier 1 common capital ratio removes preferred stock and qualifying trust preferred securities from Tier 1 capital as defined by and calculated in conformity with bank regulations. The tangible common equity removes preferred stock and the effect of intangible assets from capital and the effect of intangible assets from total assets. Comerica believes these measurements are meaningful measures of capital adequacy used by investors, regulators, management and others to evaluate the adequacy of common equity and to compare against other companies in the industry.